IgA nephropathy went from zero disease-specific drugs to five FDA-approved agents across four mechanisms in under five years.

Until December 2021, no therapy was approved specifically for IgA nephropathy, and management rested on renin-angiotensin system blockade and blood-pressure control. By mid-2026 the FDA had approved five disease-specific agents across four mechanisms: targeted-release budesonide (Tarpeyo), the dual endothelin/angiotensin antagonist sparsentan (Filspari), the selective endothelin-A antagonist atrasentan (Vanrafia), the oral complement inhibitor iptacopan (Fabhalta) and the anti-APRIL antibody sibeprenlimab (Voyxact). Four are oral; sibeprenlimab is a self-administered subcutaneous injection.

Every agent won accelerated approval on proteinuria reduction, and budesonide and sparsentan have since added eGFR-slope confirmation. The commercial contest is now between mechanisms: whether a prescriber layers an endothelin antagonist, a complement inhibitor or an APRIL inhibitor onto optimized supportive care of RAS blockade plus an SGLT2 inhibitor. IgA nephropathy still carries a 30 to 40% lifetime risk of progression to kidney failure, with median kidney survival of roughly 11 years from diagnosis, the urgency underwriting this launch wave.

Five mechanisms now compete for the same proteinuric patient before any head-to-head data exists.

Five questions this report answers:

Q1 - How do the four mechanism classes differentiate on proteinuria reduction, eGFR-slope evidence and dosing route?

Q2 - How are US payers gating access through biopsy confirmation, proteinuria thresholds and RASi/SGLT2i step-through?

Q3 - What does the Phase 3 anti-APRIL pipeline and the 2026 ICER review mean for current leaders?

Q4 - Why does sparsentan's REMS hepatotoxicity monitoring create access friction versus REMS-free competitors?

Q5 - What lifetime progression risk and median kidney survival define the clinical urgency behind this launch wave?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#IgANephropathy #US #CompetitiveIntelligence #AXLRx #RareDisease

Live report page:  https://axlrx.ai/iga-nephropathy/competitive-intelligence/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-   hello@axlrx.ai

Web-   https://axlrx.ai/